Notably, the combination of anti-LAG3 and anti-PD-1 may be more advantageous, as it has shown a better safety profile in advanced melanoma compared to the combination of anti-CTLA-4 and anti-PD-1 [134]. Here, CTLA4 is linked to melanoma.